
Opinion|Videos|November 19, 2024
Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice
This episode explores management strategies for hematologic toxicities arising within the first 3 weeks of treatment with HER3-DXd, discusses the potential integration of HER3-DXd into clinical practice upon approval, and identifies unmet needs and suitable patient populations for future clinical trials evaluating HER3-DXd based on insights from the HERTHENA-Lung01 trial results.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss your management approach to hematologic toxicities, which might occur within the first 3 weeks of treatment with HER3-DXd.
- If HER3-DXd is approved, where would you integrate HER3-DXd, and in what setting?
- What are your thoughts on the unmet needs for HER3-DXd? Which patient populations may be the most appropriate for future clinical trials evaluating HER3-DXd, based on the HERTHENA-Lung01 results?
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

